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Abstract
Nosocomial yeast infections have significantly increased during the past two decades in
industrialized countries, including Taiwan. This has been associated with the emergence of
resistance to fluconazole and other antifungal drugs. The medical records of 88 patients, colonized
or infected with Candida species, from nine of the 22 hospitals that provided clinical isolates to the
Taiwan Surveillance of Antimicrobial Resistance of Yeasts (TSARY) program in 1999 were
reviewed. A total of 35 patients contributed fluconazole resistant strains [minimum inhibitory
concentrations (MICs) ^ 64 mg/l], while the remaining 53 patients contributed susceptible ones
(MICs % 8 mg/l). Fluconazole resistance was more frequent among isolates of Candida tropicalis
(46.5%) than either C. albicans (36.8%) or C. glabrata (30.8%). There was no significant difference in
demographic characteristics or underlying diseases among patients contributing strains different in
drug susceptibility.
Background
Nosocomial infections caused by yeasts have increased
significantly in the past two decades in Taiwan as well as
other industrialized countries [1-4]. Infections by Candida
species are important causes of morbidity and mortality in
immunocompromised patients. The increase in the prev-
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alence of fungal infections is closely associated with inva-
sive medical procedures and the intense use of antibiotics
in high-risk patients [5,6]. Resistance to antifungals has
emerged in association with the increased use of these
drugs [7-9].
The Taiwan Surveillance of Antimicrobial Resistance of
Yeasts (TSARY) program was first implemented by the
National Health Research Institutes (NHRI) in 1999 to
prospectively assess the magnitude of the problem of
yeast infection and drug resistance. Clinical isolates of
yeasts were obtained from 22 geographically representa-
tive hospitals in Taiwan. Emergence of fluconazole resist-
ant Candida species was documented in 1999 shortly after
the surveillance program was instituted [9-11]. The survey
revealed that 8.4% of the collected 632 clinical isolates
were resistant [minimum inhibitory concentration (MIC)
^ 64 mg/l] to fluconazole [12]. Furthermore, there is an
association between the rate of fluconazole resistance and
the number of non-albicans Candida  species collected
from different regions and hospital types [13,14]. This
study was a follow-up, designed to determine whether
intrinsic host factors of patients might influence the fre-
quency of colonization or infection by fluconazole resist-
ant strains.
Methods
Subjects
Yeast isolates were collected as described [15] from the 22
hospitals participating in TSARY in 1999. In principle,
only one isolate was accepted from each patient. The
number of clinical isolates with MICs ^ 64 mg/l contrib-
uted from each hospital participating in TSARY program
in 1999 ranging from none to ten [13,16]. Therefore, we
chose hospitals contributed at least three clinical isolates
with MICs ^ 64 mg/l for this study. In total, there were 40
isolates with MICs ^ 64 mg/l from nine chosen hospitals.
However, medical information of five patients was not
available. Thus, we have reviewed all 35 available ones.
Patients with resistant strains were matched at a ratio of
about 1:2 with those with susceptible strains according to
the body sites from which the yeasts were isolated in the
same hospital. Each hospital contributed from 7 to 21
patients into the study. Clinical data were recorded on
standardized forms and analyzed according to demo-
graphic characteristics, hospital unit, duration of stay, pre-
disposing factors, antimicrobial therapy, underlying
illnesses, and laboratory findings. The definition of diabe-
tes, hypertension, pulmonary diseases, bacterial infection,
antifungal, antibiotics, antituberculous agents, dialysis,
catheter insertion, and mobility affected were recorded
when the Candida  species were isolated. The outcome
(mortality) was documented within three months after
those stains were isolated. The protocol was approved by
Institutional Review Board (IRB) of the National Health
Research Institutes.
Susceptibility tests
The MICs to fluconazole were determined according to
the guidelines of the Clinical and Laboratory Standards
Institute (CLSI) for in vitro antifungal susceptibility testing
[12]. The RPMI medium 1640 (31800-022) provided by
Gibco BRL was used for the testing. Strains from American
Type Culture Collection including Candida albicans
(ATCC 90028), Candida krusei (ATCC 6258), and Candida
parapsilosis (ATCC 22019) were used as the standard con-
trols. The final growth of each isolate was measured by
Biotrak II plate reader (Amershan Biosciences, Biochrom
Ltd., Cambridge England) after incubated at 35°C for 48
hours. The MICs of fluconazole were defined as the mini-
mum inhibitory concentrations of drugs capable of reduc-
ing the turbidity of cells to greater than 50%. Isolates with
MIC ^ 64 mg/l were considered to be resistant, whereas
those with MIC % 8 mg/l were susceptible. Isolates with
MICs falling in between (16 – 32 mg/l) were susceptible-
dose dependent.
Statistical analysis
The chi-square test or Fisher's exact test were used for cat-
egorical variables. The Student T-test was used for contin-
uous variables. Logistic regression was used to assess the
independent effect of factors that were significant in the
univariate analysis or were important to the association of
interest. A probability (P) < 0.05 was considered signifi-
cant.
Results
A total of 35 patients from nine hospitals were selected
and each one of them has contributed one clinical fluco-
nazole resistant isolate. As a comparison, we have also
reviewed 53 patients contributing susceptible isolates
(with MICs % 8 mg/l) from the same nine hospitals. Of
the 88 isolates, there were three Candida species and their
distribution in relation to the susceptibility to fluconazole
is shown in Table 1. It shows that fluconazole resistance
was found to be more frequent in C. tropicalis than either
C. albicans or C. glabrata. The distribution of body sites
from which the yeasts were isolated is shown in Table 2.
Most isolates were from urine (52.3%) and sputum
(23.9%) and candidemia was diagnosed in six patients
(6.8%). Both C. glabrata and C. tropicalis were isolated
more frequently from the urine than C. albicans (61.5%
vs. 60.5% vs. 21.0%, respectively), whereas C. albicans was
dominant in sputum than C. glabrata or  C. tropicalis
(47.4% vs. 15.4% vs. 18.6%, respectively).
The analysis of fluconazole susceptibility according to
characteristics of different patients is shown in Table 3.
There was no significant difference correlated to host fac-Journal of Negative Results in BioMedicine 2008, 7:12 http://www.jnrbm.com/content/7/1/12
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tors such as different demographic characteristics and
underlying diseases other than the possibility of pulmo-
nary tuberculosis. The observation that patients with pul-
monary diseases, particularly those receiving
antituberculous agents were found to be more frequently
colonized or infected with fluconazole resistant yeasts
requires further investigation. Although patients' ages did
not significantly differ between two groups, we still adjust
its effect in the multivariate analysis because age might
influence hosts' underlying conditions the acquisition of
infections. In a logistic regression, which included the
presence of pulmonary diseases (yes/no), use of antitu-
berculous agents (yes/no) and age (continuous in years),
the former two showed some associations but age did not
(p = 0.23, details no shown). Use of antituberculous
agents was associated with an odds ratio (OR) = 4.2, p =
0.05 for the resistance to the fluconazole, while the pres-
ence of pulmonary diseases was with OR = 2.7, p = 0.1.
Discussion
It is well established that mechanically supported or
immunocompromised patients with invasive devices are
at increasing risk of colonization and infection with path-
ogenic yeasts [5,17]. The findings of this study further sug-
gest that there is no difference in frequency between
fluconazole resistant and susceptible Candida species to
colonize or infect individual patients according to the
host factors analyzed. Hence, fluconazole resistant strains
do not appear to have more advantage than susceptible
ones in these patients. Many nosocomial Candida infec-
tions are endogenously acquired [18-21]. It is much more
likely that the increase of fluconazole resistant yeasts has
resulted from the intense use of fluconazole in response to
increasing prevalence of nosocomial yeast infections.
In the previous study, the resistant rate was found to asso-
ciate with regions and hospital types [13]. In this study,
we set out to investigate whether the hosts per se was an
influencing factor, since regional difference may be a
reflection of host characters. As it turned out, patients
receiving antituberculous agents had higher occurrence to
be colonized or infected with fluconazole resistant strains.
These 10 ten patients receiving antituberculous agents
were not associated with either regions or types of hospi-
tal.
Among HIV-infected patients, treatment with antitubercu-
lous drugs, previous history of tuberculosis, and flucona-
zole exposure are the risks for development of
oropharyngeal colonization or infections by fluconazole-
resistant Candida strains [22]. Noteworthily, findings
from this study indicate that non-HIV infected patients
receiving antituberculous agents had higher occurrence to
be colonized or infected with fluconazole resistant strains.
Interestingly, a link between mycobacterial infections and
oropharyngeal candidiasis in HIV-infected patients has
been reported. The prevalence of Candida species coloni-
zation or infections in AIDS patients in the tuberculous
Table 1: Distribution of fluconazole susceptibilities among Candida species isolated from patients in the nine hospitals
C. albicans C. glabrata C. tropicalis Total
MIC (mg/l) Number % Number % Number % Number %
^ 6 4 7 3 6 . 8 8 3 0 . 82 04 6 . 53 53 9 . 8
% 8 1 26 3 . 21 86 9 . 22 35 3 . 55 36 0 . 2
Total 19 100 26 100 43 100 88 100
MIC, minimum inhibitory concentration.
Table 2: Distribution of body sites of Candida species with different fluconazole susceptibility
MICs ^ 64 mg/l MICs % 8 mg/l Total
Source C. albicans C. glabrata C. tropicalis Subtotal C. albicans C. glabrata C. tropicalis Subtotal number %
Urine 0 5 11 16 4 11 15 30 46 52.3
Sputum 4 1 5 10 5 3 3 11 21 23.9
B l o o d 00 3 3 03 0 3 6 6 . 8
W o u n d 2 00 2 1 02 3 5 5 . 7
F l u i d 0 10 1 1 01 2 3 3 . 4
Genital tract 1 1 1 3 1 1 1 3 6 6.8
Catheter tip 0 0 0 0 0 0 1 1 1 1.1
Total 7 8 20 35 12 18 23 53 88 100
MIC, minimum inhibitory concentration; Fluid consisted of ascites, dialysate, and peritoneal fluid.Journal of Negative Results in BioMedicine 2008, 7:12 http://www.jnrbm.com/content/7/1/12
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group was 2.5-fold higher than that without tuberculosis
[23]. One possible explanation for this phenomenon is
that antituberculous agents may change the microbial
ecosystem in the body to favor Candida species [22]. Anti-
biotics, such as quinolones, reduces the effects of antifun-
gal agents in a murine model of invasive candidiasis [24].
Hence, antituberculous agents may also antagonize the
effects of antifungal agents to prolong survival of Candida
species and consequently the development of drug resist-
ance. The mechanism by which the usage of antitubercu-
lous agents is a risk for colonizing or infecting with
fluconazole resistant strains is worthy of further study by
a larger series.
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